Boston Scientific (BSX) reported second-quarter 2026 net sales of $5.442 billion, up 7.5% on a reported basis from the prior-year period. GAAP net income attributable to common stockholders was $907 million, or $0.61 per diluted share.
The company reported adjusted EPS of $0.86 for the period and updated its 2026 outlook, estimating full-year reported net sales growth of about 5.5% to 6.5% and adjusted EPS of $3.28 to $3.32.
- MedSurg net sales grew 5.9% on a reported basis, while Cardiovascular net sales grew 8.3%.
- Regional reported net sales growth was 6.2% in the U.S., 6.1% in EMEA, 11.2% in APAC and 22.4% in LACA.
- The company completed a previously announced $2 billion accelerated share repurchase program, repurchasing about 40 million shares.
- Boston Scientific invested $1.5 billion in MiRus LLC for an approximately 34% equity stake and an exclusive option to acquire the MiRus TAVR business.
- The company received FDA 510(k) clearance for the TruSelect 2.6 Microcatheter.
$BSX Insider Trading Activity
$BSX insiders have traded $BSX stock on the open market 6 times in the past 6 months. Of those trades, 4 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $BSX stock by insiders over the last 6 months:
- MICHAEL F MAHONEY (Chairman, President & CEO) has made 0 purchases and 2 sales selling 160,901 shares for an estimated $15,043,394.
- DAVID C HABIGER has made 2 purchases buying 4,450 shares for an estimated $251,098 and 0 sales.
- EDWARD J LUDWIG purchased 3,580 shares for an estimated $202,914
- CHERYL PEGUS purchased 1,770 shares for an estimated $99,987
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$BSX Hedge Fund Activity
We have seen 705 institutional investors add shares of $BSX stock to their portfolio, and 947 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC removed 23,160,546 shares (-23.8%) from their portfolio in Q1 2026, for an estimated $1,433,869,402
- CAPITAL WORLD INVESTORS removed 11,841,837 shares (-43.6%) from their portfolio in Q1 2026, for an estimated $733,128,128
- WELLINGTON MANAGEMENT GROUP LLP added 9,124,317 shares (+94.0%) to their portfolio in Q1 2026, for an estimated $564,886,465
- FRANKLIN RESOURCES INC added 8,822,659 shares (+155.4%) to their portfolio in Q1 2026, for an estimated $546,210,818
- FISHER ASSET MANAGEMENT, LLC removed 8,687,613 shares (-95.1%) from their portfolio in Q1 2026, for an estimated $537,850,120
- TWO SIGMA INVESTMENTS, LP added 6,939,887 shares (+280.8%) to their portfolio in Q1 2026, for an estimated $429,648,404
- MILLENNIUM MANAGEMENT LLC removed 6,926,986 shares (-61.5%) from their portfolio in Q1 2026, for an estimated $428,849,703
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$BSX Congressional Stock Trading
Members of Congress have traded $BSX stock 9 times in the past 6 months. Of those trades, 7 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $BSX stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 7 times. They made 6 purchases worth up to $90,000 on 06/05, 05/29, 05/19, 05/11, 02/10, 01/30 and 1 sale worth up to $15,000 on 06/05.
- SENATOR JOHN BOOZMAN sold up to $15,000 on 06/04.
- SENATOR ALAN ARMSTRONG purchased up to $15,000 on 03/27.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
